Galectin Therapeutics Inc GALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GALT is a good fit for your portfolio.
News
-
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
-
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
-
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
-
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
-
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
-
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.84–1.93
- 52-Week Range
- $1.02–2.47
- Bid/Ask
- $1.50 / $2.05
- Market Cap
- $117.51 Mil
- Volume/Avg
- 90,954 / 57,203
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
GALT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GALT
|
|---|---|
Quick Ratio | 1.94 |
Current Ratio | 2.05 |
Interest Coverage | −17.59 |
Quick Ratio
GALT
Profitability
|
Metric
|
GALT
|
|---|---|
Return on Assets (Normalized) | −190.65% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −434.82% |
Return on Assets
GALT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mqjv | $431.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Phvhfx | $91.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vlcvlz | $90.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Vtqmrk | $41.3 Bil | |
MRNA
| Moderna Inc | Zzd | $30.6 Bil | |
ARGX
| argenx SE ADR | Yglz | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Crqf | $24.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hhwsyy | $21.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qjyvlt | $17.5 Bil | |
INCY
| Incyte Corp | Mnkckr | $12.3 Bil |